How Many Theranostics Centers Will We Need in the United States?
Johannes Czernin, Jérémie Calais
Abstract
![Figure][1]</img> Johannes Czernin ![Figure][1]</img> Jeremie Calais Lutetium-177-PSMA-617 (PLUVICTO) has been approved by the U.S. Food and Drug Administration for patients with prostate-specific membrane antigen (PSMA)–positive metastatic castration-resistant prostate cancer (mCRPC) who
Topics & Concepts
Food and drug administrationProstate cancerMedicineOncologyCancerInternal medicinePharmacologyProstate Cancer Treatment and ResearchNeuroendocrine Tumor Research AdvancesRadiopharmaceutical Chemistry and Applications